Survodutide
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
Boehringer Ingelheim · Phase 1 · Completed · Enrollment 88
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| BI 1820237 treatment group | n/r | n/r | n/r | n/r |
| Placebo group | n/r | n/r | n/r | n/r |
| BI 1820237 + semaglutide treatment group | n/r | n/r | n/r | n/r |
| placebo + semaglutide group | n/r | n/r | n/r | n/r |
| BI 1820237 + BI 456906 treatment group | n/r | n/r | n/r | n/r |
| placebo + BI 456906 group | n/r | n/r | n/r | n/r |
Not shown
- BI 1820237 treatment group: endpoint not reported
- Placebo group: endpoint not reported
- BI 1820237 + semaglutide treatment group: endpoint not reported
- placebo + semaglutide group: endpoint not reported
- BI 1820237 + BI 456906 treatment group: endpoint not reported
- placebo + BI 456906 group: endpoint not reported